The rollercoaster ride to anti-cancer antibodies - A recent Keystone meeting highlighted the progress in developing antibody-based therapeutics for cancer.

被引：0
作者：
Weiner, LM
Carter, P
机构：
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Seattle Genet, Antibody Technol, Seattle, WA 98021 USA
来源：
NATURE BIOTECHNOLOGY | 2003年 / 21卷 / 05期
关键词：
D O I：
10.1038/nbt0503-510
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：510 / 511
页数：2
相关论文
共 4 条
[1]  
*BANFF CTR, 2003, KEYST S ANT BAS THER
[2]   Fc receptors are required in passive and active immunity to melanoma [J].
Clynes, R ;
Takechi, Y ;
Moroi, Y ;
Houghton, A ;
Ravetch, JV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :652-656
[3]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[4]   CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY [J].
KOHLER, G ;
MILSTEIN, C .
NATURE, 1975, 256 (5517) :495-497
1